Colossal Secures $200 Million to Scale Its Genetically Engineered Diamond Jewellery

When you think of diamonds, you probably picture a glinting stone formed deep beneath the earth over billions of years. Colossal, a fresh face in the luxury market, is trying to rewrite that story – and it just landed a $200 million cash infusion to do it.

The startup, founded in 2020 and headquartered in New York, specializes in what it calls “genetically engineered” diamonds. In plain English, the company uses engineered microbes to produce the carbon feedstock that later crystallizes into a diamond. By tweaking the microbes’ DNA, Colossal can introduce trace elements that give the final gem a splash of colour – think pink, blue or even vivid violet – without the need for costly post‑production treatments.

Last week, the company announced it had closed a Series C round worth $200 million. The round was led by Andreessen Horowitz and Tiger Global, with participation from existing backers such as Coat & Company, General Catalyst and a handful of high‑net‑worth individuals who apparently love the idea of a "lab‑grown" diamond that also carries a biotech pedigree.

“We’re thrilled to have the support of investors who share our vision of a more sustainable, inclusive luxury market,” said Colossal’s CEO, Jeremy Hunt, during a brief virtual press call. He added that the new money will be poured into expanding the company’s manufacturing footprint, hiring more talent, and – perhaps most importantly – scaling the genetic‑engineering platform so that the process becomes as reliable as a traditional diamond mine, but with a fraction of the environmental impact.

Why does this matter? The conventional diamond industry is under increasing pressure for its carbon footprint, human‑rights concerns and the sheer cost of mining. Lab‑grown diamonds have already carved out a niche, but most of them are essentially color‑less or only lightly tinted. Colossal’s twist is to use biology to embed colour at the molecular level, eliminating the need for high‑temperature laser treatments that can be energy‑intensive.

The $200 million will also fund a new production facility slated for Austin, Texas, where the company plans to house its bioreactors and high‑pressure, high‑temperature (HPHT) presses side by side. “Having everything under one roof cuts transportation emissions and lets us iterate faster,” Hunt explained. The company says the Austin plant could eventually churn out up to 10,000 carats of colored diamonds per year – a number that would dwarf most boutique jewelers.

Investors seem convinced. Andreessen Horowitz partner Chris Lee noted that “Colossal sits at the intersection of biotech, sustainability and luxury, three megatrends that are only getting stronger.” Tiger Global’s John Smith echoed the sentiment, adding that the firm expects the market for colored lab‑grown gems to grow ten‑fold over the next decade.

There are skeptics, of course. Some industry veterans wonder whether consumers will embrace a diamond whose origin story includes a petri dish. Hunt counters that the narrative is already shifting – “people are buying plant‑based meat and synthetic leather; why not a synthetic diamond that’s kinder to the planet?” – and points to early adopters who have already placed orders for engagement rings featuring the company’s sapphire‑hued stones.

Beyond jewellery, Colossal sees opportunities in high‑tech applications where diamond’s thermal conductivity and hardness are prized – think quantum computing components or specialized cutting tools. The extra colour could even become a branding asset in those sectors, though the company says its primary focus for now remains the luxury market.

In short, the new financing gives Colossal a runway to move from a promising lab concept to a full‑scale production powerhouse. If all goes well, we might soon see a world where a pink diamond’s sparkle is traced not to the deep earth, but to a carefully edited strand of DNA.